摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[4-Amino-7-(4-{2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-phenol | 344891-49-2

中文名称
——
中文别名
——
英文名称
3-[4-Amino-7-(4-{2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-phenol
英文别名
3-[4-amino-7-[4-[2-[2-hydroxyethyl(methyl)amino]ethyl]phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol
3-[4-Amino-7-(4-{2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-phenol化学式
CAS
344891-49-2
化学式
C23H25N5O2
mdl
——
分子量
403.484
InChiKey
LRSZQKQTVQFILF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    100
  • 氢给体数:
    3
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    3-[4-Amino-7-(4-{2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-phenol磷酸三甲酯 作用下, 生成 ({2-[(2-{4-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-ethyl)-methyl-amino]-ethoxy}-hydroxy-phosphorylmethyl)-phosphonic acid
    参考文献:
    名称:
    Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues
    摘要:
    Src tyrosine kinase is a therapeutic target for bone diseases that has been validated by gene knockout studies. Furthermore, in vitro cellular studies implicate that Src has a positive regulatory role in osteoclasts and a negative regulatory role in osteoblasts. The potential use of Src inhibitors for osteoporosis therapy has been previously shown by novel bone-targeted ligands of the Src SH2 (e.g., AP22408) and non-bone-targeted, ATP-based inhibitors of Src kinase. Significant to this study, compounds 212 exemplify novel analogues of known pyrrolopyrimidine and pyrazolopyrimidine template-based Src kinase inhibitors that incorporate bone-targeting group modifications designed to provide tissue (bone) selectivity and diminished side effects. Accordingly, we report here the structure-based design, synthetic chemistry and biological testing of these compounds and proof-of-concept studies thereof. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(03)00647-4
  • 作为产物:
    描述:
    2-((4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenethyl)(methyl)amino)ethanol 在 三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 5.0h, 生成 3-[4-Amino-7-(4-{2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-phenol
    参考文献:
    名称:
    Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues
    摘要:
    Src tyrosine kinase is a therapeutic target for bone diseases that has been validated by gene knockout studies. Furthermore, in vitro cellular studies implicate that Src has a positive regulatory role in osteoclasts and a negative regulatory role in osteoblasts. The potential use of Src inhibitors for osteoporosis therapy has been previously shown by novel bone-targeted ligands of the Src SH2 (e.g., AP22408) and non-bone-targeted, ATP-based inhibitors of Src kinase. Significant to this study, compounds 212 exemplify novel analogues of known pyrrolopyrimidine and pyrazolopyrimidine template-based Src kinase inhibitors that incorporate bone-targeting group modifications designed to provide tissue (bone) selectivity and diminished side effects. Accordingly, we report here the structure-based design, synthetic chemistry and biological testing of these compounds and proof-of-concept studies thereof. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(03)00647-4
点击查看最新优质反应信息